SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,408,288 | +13.7% | 51,080 | +24.0% | 0.00% | 0.0% |
| Q2 2023 | $1,238,194 | -6.2% | 41,190 | +13.1% | 0.00% | 0.0% |
| Q1 2023 | $1,319,730 | +1.9% | 36,426 | +0.3% | 0.00% | 0.0% |
| Q4 2022 | $1,295,690 | +11.4% | 36,325 | +5.8% | 0.00% | 0.0% |
| Q3 2022 | $1,163,000 | +28.8% | 34,346 | +10.0% | 0.00% | +100.0% |
| Q2 2022 | $903,000 | +2.0% | 31,212 | +14.0% | 0.00% | 0.0% |
| Q1 2022 | $885,000 | +17.2% | 27,383 | +5.8% | 0.00% | 0.0% |
| Q4 2021 | $755,000 | +22.6% | 25,879 | +12.1% | 0.00% | 0.0% |
| Q3 2021 | $616,000 | +15.4% | 23,085 | +33.0% | 0.00% | 0.0% |
| Q2 2021 | $534,000 | +39.8% | 17,351 | +18.9% | 0.00% | 0.0% |
| Q1 2021 | $382,000 | +19.4% | 14,590 | +14.8% | 0.00% | 0.0% |
| Q4 2020 | $320,000 | +34.5% | 12,707 | +11.4% | 0.00% | – |
| Q3 2020 | $238,000 | -8.5% | 11,411 | +4.1% | 0.00% | -100.0% |
| Q2 2020 | $260,000 | +11.1% | 10,962 | -13.6% | 0.00% | 0.0% |
| Q1 2020 | $234,000 | -50.0% | 12,693 | -36.7% | 0.00% | 0.0% |
| Q4 2019 | $468,000 | -56.5% | 20,042 | -49.1% | 0.00% | -66.7% |
| Q3 2019 | $1,075,000 | -47.9% | 39,370 | -37.0% | 0.00% | -40.0% |
| Q2 2019 | $2,065,000 | +70.1% | 62,501 | +81.0% | 0.01% | +66.7% |
| Q1 2019 | $1,214,000 | +16.2% | 34,539 | +9.4% | 0.00% | 0.0% |
| Q4 2018 | $1,045,000 | -36.6% | 31,558 | -3.5% | 0.00% | -40.0% |
| Q3 2018 | $1,647,000 | -29.3% | 32,693 | -15.9% | 0.01% | -28.6% |
| Q2 2018 | $2,328,000 | +22.7% | 38,880 | -5.8% | 0.01% | +16.7% |
| Q1 2018 | $1,898,000 | +3.0% | 41,261 | -10.6% | 0.01% | 0.0% |
| Q4 2017 | $1,843,000 | +1.0% | 46,179 | +1.3% | 0.01% | 0.0% |
| Q3 2017 | $1,825,000 | -12.8% | 45,575 | -6.0% | 0.01% | -25.0% |
| Q2 2017 | $2,093,000 | +30.2% | 48,505 | -5.5% | 0.01% | +33.3% |
| Q1 2017 | $1,607,000 | +25.7% | 51,301 | +1.6% | 0.01% | +20.0% |
| Q4 2016 | $1,278,000 | +57.0% | 50,470 | +54.3% | 0.01% | +25.0% |
| Q3 2016 | $814,000 | +3.7% | 32,700 | -15.1% | 0.00% | 0.0% |
| Q2 2016 | $785,000 | -54.1% | 38,507 | -65.7% | 0.00% | -55.6% |
| Q1 2016 | $1,711,000 | -0.6% | 112,210 | -12.4% | 0.01% | 0.0% |
| Q4 2015 | $1,722,000 | +7.9% | 128,128 | +12.6% | 0.01% | 0.0% |
| Q3 2015 | $1,596,000 | -60.1% | 113,768 | -51.7% | 0.01% | -10.0% |
| Q2 2015 | $4,002,000 | +202.7% | 235,730 | +115.6% | 0.01% | +42.9% |
| Q1 2015 | $1,322,000 | +336.3% | 109,332 | +199.5% | 0.01% | +250.0% |
| Q4 2014 | $303,000 | -3.8% | 36,505 | +0.7% | 0.00% | -33.3% |
| Q3 2014 | $315,000 | +7.1% | 36,255 | +35.3% | 0.00% | 0.0% |
| Q2 2014 | $294,000 | +33.6% | 26,805 | +8.9% | 0.00% | +50.0% |
| Q1 2014 | $220,000 | – | 24,605 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |